Sign in
REPL Stock Price, Chart, Stats & News
Replimune Group, Inc.
Save
923.16M
Market cap
–
Current P/E
–
Forward P/E
REPL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.31% |
ROA | -94.38% |
ROE | -102.69% |
D/E | 0.37x |
Interest coverage ratio | -50.39x |
REPL valuation
P/E | – |
P/S | – |
P/B | 3.16x |
P/CF | -2.39x |
P/FCF | -2.10x |
P/OCF | -2.39x |
PEG | -3.81x |
EV multiple | -2.06x |
About
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1.
Similar securities
Based on sector and market capitalization
Report issue